Centurium Capital Closes Its Debut Dollar Fund at Over US$2 Billion

Beijing, China, July 3, 2019 – Centurium Capital, a leading private equity firm in China, today announced the successful close of its debut US dollar fund, Centurium Capital Partners 2018 L.P. at over US$2 billion, far exceeding its target size. The fund has secured overwhelming interests from global institutional investors including pension funds, sovereign wealth funds, family offices, corporate pensions, FOFs, and other financial institutions. The fund was launched in March 2018 and reached a significant first close of nearly US$1 billion in June 2018.

Centurium Capital primarily focuses on investing into China’s consumer, services and healthcare sectors. The firm’s investment theses are built around its core investment strategy of “invest to transform”. Centurium seeks to invest in control or significant minority private equity stakes with a particular focus on in-depth engagement to improve operational efficiency and solve structural deficiencies.

David Li, Chairman and CEO of Centurium Capital, commented, “The successful fundraise is a vote of confidence in China’s long term growth potential by global investors, as well as a strong testament to our firm’s strategy and ability of investing to transform. In the context of China’s new norm of economic growth model and fast-evolving business landscape, Chinese companies and entrepreneurs are faced with unprecedented new challenges as well as new opportunities. With a unique combination of global best practice and local expertise and experience, Centurium Capital is well positioned to provide bespoke solutions to these challenges and opportunities by being a long term partner of capital and mindshare to our portfolio companies and entrepreneurs”.

Since its first close, Centurium Capital has made a number of investments, including Luckin Coffee (NASDAQ: LK), a leading internet based on demand coffee brand and retail chain in China, China Biologic Products (NASDAQ: CBPO), one of the largest plasma-based biopharmaceutical companies in China, and LOHO, China’s leading fast-fashion eyewear brand and retailer with a vertically integrated supply chain.